Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_5809_T1_RNA

— · C

c3d4e3d6-7aff-59e7-8050-54683dcd180e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_GAMMA_RESPONSE+0.510
  • INTERFERON_ALPHA_RESPONSE+0.480
  • ALLOGRAFT_REJECTION+0.460
  • INFLAMMATORY_RESPONSE+0.440
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • COMPLEMENT+0.410
  • TNFA_SIGNALING_VIA_NFKB+0.390
  • COAGULATION+0.370
  • IL6_JAK_STAT3_SIGNALING+0.350
  • PANCREAS_BETA_CELLS+0.330

Top 10 suppressed

  • MYC_TARGETS_V2-0.420
  • E2F_TARGETS-0.390
  • G2M_CHECKPOINT-0.390
  • MITOTIC_SPINDLE-0.340
  • NOTCH_SIGNALING-0.330
  • DNA_REPAIR-0.310
  • WNT_BETA_CATENIN_SIGNALING-0.290
  • ESTROGEN_RESPONSE_EARLY-0.280
  • HEME_METABOLISM-0.200
  • MYC_TARGETS_V1-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1sclcM1201764A_S68.txt
lung-landscapes@6
—cohortMD20.868
2TCGA-A8-A0A7-01A-11R-A00Z-07
breast-umap@18
—D0.866
3f40a9044-a36a-4091-8783-0815792c56f7
colon-landscapes@1
——0.852
420100100.Her2HRpos
breast-umap@18
—D0.846
5SRR8526727
lung-landscapes@6
—cohortMD20.842
6MDT-AP-0410
medullo-epn-umap@date-based
MedMedulloblastoma0.841
7BS_FAQQ0GCQ
brain-umap@2
Ganglioglioma—0.841
8TCGA-AO-A0JE-01A-11R-A056-07
breast-umap@18
—C0.839
9MBCProject_3554_T2_RNA
breast-umap@18
—A0.833
10BSR_15_0113_A1_S103
breast-umap@18
—C0.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_GAMMA_RESPONSE0.510Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.480Inavolisib— uncovered
ALLOGRAFT_REJECTION0.460Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.440Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
COMPLEMENT0.410Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.390Inavolisib— uncovered
COAGULATION0.370Binimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.350Inavolisib— uncovered
PANCREAS_BETA_CELLS0.330Cobimetinib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.280Remibrutinib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
IL2_STAT5_SIGNALING0.260Idelalisib— uncovered
PROTEIN_SECRETION0.250Remibrutinib— uncovered
ANDROGEN_RESPONSE0.240Inavolisib— uncovered
APOPTOSIS0.210Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.180Inavolisib— uncovered